Kavya Keerthana: A Potentially Important Advance in Polycythemia Vera
Kavya Keerthana, Hematologist at Prime Health, shared a post on LinkedIn:
“A potentially important advance in Polycythemia Vera (PV).
In PV, excess red blood cells increase the risk of blood clots, stroke and heart attack.
For years, regular phlebotomy has been a cornerstone of treatment—but repeated blood removal can also lead to iron deficiency.
The FDA has approved rusfertide, a hepcidin mimetic that offers a different approach by regulating iron availability and reducing excessive red blood cell production.
In the Phase 3 VERIFY trial, 76.9 percent of patients receiving rusfertide achieved clinical response, with fewer phlebotomies and improvements in symptoms such as fatigue.
A fascinating shift in how we think about managing PV.”
Find more posts featuring Kavya Keerthana on Hemostasis Today.
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period